Harvard Bioscience Inc (HBIO)
3.55
-0.14
(-3.79%)
USD |
NASDAQ |
Apr 25, 13:22
Harvard Bioscience Enterprise Value: 192.42M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 24, 2024 | 192.42M |
| April 23, 2024 | 193.73M |
| April 22, 2024 | 192.86M |
| April 19, 2024 | 192.86M |
| April 18, 2024 | 204.58M |
| April 17, 2024 | 209.78M |
| April 16, 2024 | 213.69M |
| April 15, 2024 | 224.97M |
| April 12, 2024 | 216.29M |
| April 11, 2024 | 220.85M |
| April 10, 2024 | 217.16M |
| April 09, 2024 | 233.22M |
| April 08, 2024 | 219.33M |
| April 05, 2024 | 228.44M |
| April 04, 2024 | 226.27M |
| April 03, 2024 | 214.56M |
| April 02, 2024 | 213.26M |
| April 01, 2024 | 217.16M |
| March 28, 2024 | 216.29M |
| March 27, 2024 | 214.56M |
| March 26, 2024 | 206.75M |
| March 25, 2024 | 211.52M |
| March 22, 2024 | 213.26M |
| March 21, 2024 | 221.50M |
| March 20, 2024 | 223.24M |
| Date | Value |
|---|---|
| March 19, 2024 | 223.24M |
| March 18, 2024 | 212.39M |
| March 15, 2024 | 208.05M |
| March 14, 2024 | 218.46M |
| March 13, 2024 | 222.80M |
| March 12, 2024 | 217.60M |
| March 11, 2024 | 221.50M |
| March 08, 2024 | 224.10M |
| March 07, 2024 | 228.01M |
| March 06, 2024 | 210.65M |
| March 05, 2024 | 214.12M |
| March 04, 2024 | 221.93M |
| March 01, 2024 | 221.07M |
| February 29, 2024 | 220.18M |
| February 28, 2024 | 222.35M |
| February 27, 2024 | 224.08M |
| February 26, 2024 | 221.91M |
| February 23, 2024 | 223.65M |
| February 22, 2024 | 223.22M |
| February 21, 2024 | 224.95M |
| February 20, 2024 | 220.18M |
| February 16, 2024 | 228.42M |
| February 15, 2024 | 243.18M |
| February 14, 2024 | 235.80M |
| February 13, 2024 | 221.48M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
99.94M
Minimum
Mar 19 2020
382.17M
Maximum
Aug 12 2021
216.32M
Average
201.26M
Median
Jan 12 2021
Enterprise Value Benchmarks
| Bruker Corp | 12.15B |
| Azenta Inc | 1.921B |
| Bionano Genomics Inc | 14.52M |
| Akoya Biosciences Inc | 179.36M |
| Singular Genomics Systems Inc | -134.92M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.818M |
| Revenue (Quarterly) | 28.15M |
| Total Expenses (Quarterly) | 27.87M |
| EPS Diluted (Quarterly) | -0.04 |
| Gross Profit Margin (Quarterly) | 57.99% |
| Profit Margin (Quarterly) | -6.46% |
| Earnings Yield | -2.25% |
| Operating Earnings Yield | 1.25% |
| Normalized Earnings Yield | -1.917 |